Register | Forgot password?
Switch to Arabic
Monday, November 9 - 2009

Pfizer to establish new regional medical and marketing headquarters in Dubai

  • United Arab Emirates: Thursday, March 27 - 2008 at 11:38
  • PRESS RELEASE

Pfizer Inc, the world's premier research-based pharmaceutical company, today announced the establishment of its new medical and marketing headquarters in Dubai, licensed by Dubai Biotechnology and Research Park (DuBiotech), a member of TECOM Investments.

Article continues below
  • Dr. Abdulqader Alkhayat, Executive Director of DuBiotech; Zeydan Abuissa, General Manager of Pfizer; Jeffrey B. Kindler, Chairman and CEO of Pfizer; Abdullatif Almulla, CEO of TECOM Investments; Joshua Kindler; and Marwan Abdulaziz,  Director of Sales at DuBiotech; during a meeting to discuss Pfizer's future projects at DuBiotech.
    Dr. Abdulqader Alkhayat, Executive Director of DuBiotech; Zeydan Abuissa, General Manager of Pfizer; Jeffrey B. Kindler, Chairman and CEO of Pfizer; Abdullatif Almulla, CEO of TECOM Investments; Joshua Kindler; and Marwan Abdulaziz, Director of Sales at DuBiotech; during a meeting to discuss Pfizer's future projects at DuBiotech.
Pfizer's move comes as part of its strategy to establish Dubai as its regional hub for Middle East and Africa. The pharmaceutical major boasts over 1,300 employees in the Middle East with regional offices in Dubai and Cairo.

Detailing DuBiotech's advantages, Jeffrey B. Kindler, Chairman and CEO of Pfizer Inc, said: "DuBiotech has a holistic vision on how the biotechnology industry is required to operate for registering consistent growth. The biotechnology park has realised the need for top-tier talent to sustain this line of business. Our partnership with DuBiotech also offers us a solid regulatory system and the right governmental support to drive innovation, which is crucial to the development of the biotechnology industry."

Earlier in the week, His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, received Kindler on his first visit to Dubai.

"Dubai has a wonderful investor-friendly climate. The extraordinary vision of its leaders has ensured the emirate is our location of choice for setting up Pfizer's Gulf regional headquarters," added Kindler.

Dr. Al Khayat said:

"We are pleased to welcome a global research-based pharmaceutical company such as Pfizer Inc to our growing DuBiotech community. This affiliation is a singular achievement not just for DuBiotech but also for the region as we endeavour to establish Dubai as a hub for the life sciences. The presence of Pfizer will add significant value to the biotechnology industry and contribute to its development in the region."


"In our endeavour to create a regional centre of excellence, we look forward to future partnerships in clinical trials and education with Pfizer, as well as with other pharmaceutical and biotechnology giants."

The Dubai Biotechnology and Research Park aims to create a regional centre of excellence for biotechnology by bridging research, education, and industry through national and international collaborations.

Offering a complete value chain to help companies set up operations, DuBiotech currently hosts 35 licensed firms. The free zone is working closely with the UAE Ministry of Health, the Dubai Health Authority, and other relevant regulatory bodies to further grow the life sciences industry in the country.
Also consider reading:
Log in to request more information from DuBiotech

Notes and media contacts

About Pfizer
Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company taking new approaches to better health. The company discovers, develops, manufactures and delivers quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. At Pfizer, nearly 90,000 colleagues in more than 90 countries work every day to help people stay happier, healthier and longer. Worldwide, Pfizer provides treatment for over 38 million patients a day. The company's overarching purpose; Working Together for a Healthier World.

About DuBiotech
Announced in February 2005, the Dubai Biotechnology and Research Park (DuBiotech) is a science and business park dedicated to the biotechnology industry, set within a 'free zone'. DuBiotech has two arms. The first is the Foundation for Research and Innovation (FRI) that will initially focus on government-funded R&D in medicine and genetics, plant biotechnology encompassing food and agricultural biotech, environmental biotech and equine-related biotechnology. Other areas include drug discovery, stem cell research, infectious diseases and forensic research. The second arm of DuBiotech aims to set up a biotechnology industry cluster with cutting-edge infrastructure, facilities and services for incubators, R&D labs, biotech-related educational institutions, suppliers, biotech-related manufacturing companies and organizations from other sectors in the industry. DuBiotech is advised by an independent steering committee on scientific, business and ethical matters. In cooperation with global research leader, RTI International, DuBiotech is developing comprehensive regulations that address all aspects of biotech activity. Being in a 'free zone' means biotechnology firms in the park have 100 % exemption from any form of taxation for 50 years, 100 % business ownership and 100 % repatriation of capital.

For further information, please call:
Zeba Ahmad
JiWiN
The Exclusive Middle East Affiliate of Burson-Marsteller
Tel: +9714 361 3590 (direct)
+9714 361 3333 (switchboard)
Fax: +9714 388 8001

OR

Cynthia Luna-Harb
JiWiN
The Exclusive Middle East Affiliate of Burson-Marsteller
Tel: +9714 375 5878 (direct)
+9714 361 3333 (switchboard)
Fax: +9714 388 8001

Disclaimer:

Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com

Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.

For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions